Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Recurrent Clostridioides difficile infection (rCDI) is common, with symptoms ranging from diarrhea to life-threatening sepsis. This study aimed assess the real-world outcomes of patients rCDI in United States (US) who received fecal microbiota, live-jslm (RBL), first US Food and Drug Administration-approved microbiota-based therapy for prevention after antibiotic treatment. Adults RBL between July 2023 August 2024 at home or a clinic had ≥ 8 weeks follow-up experienced CDI recurrence any time administration were included. Treatment success, defined as no within RBL, was assessed overall subgroups stratified by age, number prior recurrences, duration washout period, bezlotoxumab use, setting. Among 196 176 either < but during that period. The treatment success rate 83.0%. No significant differences observed rates among based on age (< 65 years old vs. old: 85.9% 80.2%, p = 0.20), period (24 h: 80.0%, 48 84.5%, 72 85.0%, 0.68), recurrences 3 3: 82.5% 83.1%, 0.60), use (86.4% 83.7%, 1.00). Patients receiving higher compared those (87.3% 62.5%, 0.01). highly effective preventing setting, including at-home administration. effectiveness also high-risk subgroups, such recurrences.

Language: Английский

---

Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases

Expert Opinion on Biological Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 26, 2025

The microbiota composition in humans varies according to the anatomical site and is crucial for maintaining homeostasis an overall healthy state. Several gastrointestinal, vaginal, respiratory, skin diseases are associated with dysbiosis. Alternative therapies such as transplantation can help restore normal be implemented treat clinically relevant diseases. Current conducted clinical trials were included this review (after searching on MEDLINE database from years 2017 2025) fecal (FMT) against recurrent Clostridiodes difficile infection (rCDI) vaginal (VMT) bacterial vaginosis. Washed (WMT) live biotherapeutic products (LBPs) also reviewed. In microbiota-based therapy, selecting optimal donors a limitation. A stool or bank should overcome time-consuming expensive process of donor recruitment. Microbiota-based LBPs promising treatment alternatives rCDI other dysbiosis-associated Specific could engineered out fluids-derived strains achieve selection specific beneficial microorganisms Personalized treatments solutions diseases, which remains important necessity practice.

Language: Английский

---

The Microbiota–Human Health Axis

Microorganisms, Journal Year: 2025, Volume and Issue: 13(4), P. 948 - 948

Published: April 20, 2025

Trillions of microorganisms play a pivotal role in maintaining health and preventing disease humans. Their presence influences daily life, habits, energy levels, pathologies. The present narrative review synthesized recent studies microbial diversity across organ systems. composition the microbiota regulates intestinal barrier, modulates immune response, metabolism, produces essential compounds such as short-chain fatty acids neurotransmitters. Dysbiosis is associated with numerous pathologies, including metabolic, autoimmune, neurodegenerative, cardiovascular diseases. key to physiological balance reducing risk. Therapeutic interventions, probiotics, prebiotics, postbiotics, microbiome transplantation, offer promising perspectives restoring homeostasis chronic

Language: Английский

---

Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: Oct. 5, 2024

Language: Английский

---

Therapeutic potential of Parabacteroides distasonis in gastrointestinal and hepatic disease

MedComm, Journal Year: 2024, Volume and Issue: 5(12)

Published: Dec. 1, 2024

Abstract Increasing evidences indicate that the gut microbiota is involved in development and therapy of gastrointestinal hepatic disease. Imbalance occurs early stages diseases, maintaining balance provides a new strategy for treatment diseases. It has been reported Parabacteroides distasonis associated with multiple As next‐generation probiotics, several studies have demonstrated its positive regulation on disease, including inflammatory bowel colorectal cancer, fibrosis, fatty liver. The function P. metabolites mainly affect host immune system, intestinal barrier function, metabolic networks. Manipulation natural components lead to protective effect enterohepatic In this review, pathways regulated by are summarized illustrate active their impact metabolism, role action mechanism disease discussed. More importantly, can be used manipulate as strategies, challenges perspectives clinical applications

Language: Английский

---

The case for microbial intervention at weaning

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Oct. 28, 2024

Weaning, the transition from a milk-based diet to solid food, coincides with most significant shift in gut microbiome composition lifetime of mammals. Notably, this period also marks "window opportunity" where key components immune system develop, and host-microbe interactions shape long-term homeostasis thereby influencing risk autoimmune inflammatory diseases. This review provides comprehensive analysis changes nutrition, microbiota, host physiology that occur during weaning. We explore how these weaning-associated processes differ across species, lifestyles, regions intestine. Using prinicples microbial ecology, we propose weaning is an optimal for microbiome-targeted therapeutic interventions. Additionally, suggest replicating features adults could promote successful engraftment probiotics. Finally, highlight research areas deepen our understanding complex relationships between diet, commensal microbes, host, informing development more effective therapies.

Language: Английский

---

Fecal microbiota transplantation as a possibility of curing Irritable Bowel Syndrome FMT as a possibility of curing IBS

Progress in Health Sciences, Journal Year: 2024, Volume and Issue: 14(1), P. 41 - 49

Published: June 19, 2024

Introduction and Objective. Irritable Bowel Syndrome (IBS) became recently a common problem among the population of highly developed countries. Most patients suffer from chronic abdominal pain various bowel habit disorders. Although pathogenesis IBS was not yet entirely defined, intestinal dysbiosis is frequently mentioned as one most possible mechanisms. There may be way to permanently cure IBS, by replacing patient’s dysbiotic microflora with Fecal Microbiota Transplantation (FMT) healthy donor. The purpose this paper present FMT method treatment.Review methods. Search using PubMed database combined keywords: "Irritable Syndrome", "Fecal Transplantation", "Dysbiosis" "Intestinal Microbiota". An attempt made comprehensive state knowledge while indicating areas that require further research. Brief description knowledge. Effectiveness in has been clinically proven seems donor-dependent. Superdonor’s microbiota profile defined yet. gradually gaining popularity new research appears confirming long-term effectiveness procedure.Summary. Research results are promising it likely will introduced treatment routinely used clinical practice. Differences test related use material donors. It important establish exact dosage, frequency procedure, criteria for selecting superdonors, if more than donor should used, other things.

Language: Английский

---

Clostridioides difficile Infection in the Elderly: Trend Analysis from 2000 to 2019

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(13), P. 3740 - 3740

Published: June 26, 2024

Background/Objective: Clostridioides difficile infection (CDI) is a common healthcare-associated ailment, presenting major health and economic challenges, especially for the elderly. Despite its prevalence, comprehensive data about CDI's impact on elderly are limited. Methods: This study used Global Burden of Disease Study 2019 to analyze CDI trends from 2000 2019, considering factors like sex, region, sociodemographic index (SDI). Results: revealed that caused approximately 18,181 deaths 252,709 disability-adjusted life years (DALYs) among worldwide. The Americas showed highest burden, while Eastern Mediterranean saw steepest rate increase 2019. Regions with high SDI also displayed substantial impact. Conclusions: escalating burden in elderly, high-SDI areas Americas, emphasizes an urgent need targeted public strategies.

Language: Английский

---